N/A N=9,361 Systolic Blood Pressure Intervention Trial
Hypertension
Primary: Number of Participants With First Occurrence of a Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Stroke, Heart Failure (HF), or CVD Death — 243; 319…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=261 Obese Hypertension Study (0954-315)
Hypertension
Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg
Phase 4 N=229 The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
Hypertension · Diastolic Dysfunction
Primary: Change in Lateral Mitral Annular Myocardial Relaxation Velocity — 1.544; 1.476 cm/s
N/A N=126 Blood Pressure in Dialysis Patients
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
Phase 4 N=488 Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
Stage 2 Systolic Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure After 6 Weeks — 166.8; 168.5; 135.5; 142.5 mmHg
Phase 4 N=433 Nebivolol in Patients With Systolic Stage 2 Hypertension
Hypertension
Primary: Change From Baseline in Mean Seated Systolic Blood Pressure After 6 Weeks of Nebivolol Monotherapy — -18.2; -12.3 mm Hg
N/A N=146 The Effect of Pre-discharge Blood Pressure of Patients With Asymptomatic Severe Hypertension in Emergency Department
Hypertension · Emergencies · Asymptomatic Conditions
Primary: Number of Participants Who Died Within 7 Days After Discharge From the Emergency Department — 0; 0 participants
Phase 4 N=24 Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)
Hypertension
Primary: Change in Oral Glucose Tolerance Test (OGTT) Area Under Curve (AUC) After Addition of Trandolapril to Hydrochlorothiazide (HCTZ) Compared With Change in OGTT AUC After…
N/A N=5 HIRREM for Stage 1 Primary Hypertension
Hypertension · Blood Pressure · Cardiovascular Diseases
Primary: Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device. — -3.00; -6.67; -6.00; -7.67 mmHg
N/A N=200 Perioperative Blood Pressures and Chronic Hypertension
Hypertension
Primary: Performance of Blood Pressure Referral Threshold — .841 proportion
N/A N=51 Chiropractic for Hypertension in Patients
Hypertension
Primary: Unadjusted and Adjusted Changes From Baseline in Systolic and Diastolic Blood Pressure at Weeks 1, 3, 6 — -1.2; -5.3; 0.8; -1.7 mmHg
N/A N=591 Hypertension Intervention Nurse Telemedicine Study (HINTS)
Hypertension
Primary: Estimated Percentage of Participants in Blood Pressure Control at Baseline — 61; 59; 53; 64 % of particpants w/ controlled BP
N/A N=123 Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
Hypertension · High Blood Pressure · Ventricular Hypertrophy
Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg
N/A N=510 Blood Pressure Checks for Diagnosing Hypertension (BP-CHECK)
Blood Pressure
Primary: Comparative Performance of Clinic, Home, and Kiosk — -4.7; -0.1; 9.5; -7.2 millimeters of mercury — p=<0.05
N/A N=9 Spinal Cord Stimulation to Treat Hypertension
Hypertension
Primary: Change in Exercise Pressor Reflex From Baseline — 8.67; 16.29 mmHG
N/A N=106 Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
Uncontrolled Hypertension
Primary: Office Systolic Blood Pressure Reduction — -31.7; 0.9 mmHg
N/A N=56 Mindfulness Based Stress Reduction for High Blood Pressure
Hypertension
Primary: SBP — 130.2; 128.8 mm Hg
N/A N=574 Targeting of UnControlled Hypertension in Emergency Department
Hypertension · Cardiovascular Diseases · Vascular Diseases
Primary: Mean Systolic Blood Pressure (SBP) Difference at 6 Months Post-intervention Compared to Usual Care. — -9.2; -14.0 mmHg
N/A N=17 Controlling and Lowering Blood Pressure With The MOBIUSHD™
Hypertension
Primary: Adverse Events — 1; 1; 1; 1 participants
N/A N=385 Titrated Disease Management for Patients With Hypertension
Hypertension
Primary: Systolic Blood Pressure — 143.5; 143.7 mmHg
Phase 3 N=114 Irbesartan and Atenolol in Hypertensive Heart Disease
Hypertension
Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2
N/A N=199 Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
Hypertension, Systolic · Cerebrovascular Disease
Primary: Mobility - Measured by Change in Gait Speed — 0.4; 0.42 seconds
Phase 2 N=7 Mechanisms of Refractory Hypertension (Reserpine)
Refractory Hypertension
Primary: Change Ambulatory Systolic Blood Pressure — -29.3 mmHg
N/A N=24 SMS System for Patients With Uncontrolled Hypertension
Hypertension
Primary: Number of Participants Screened — 12; 12 participants
N/A N=271 Effect of Reducing Sedentary Behavior on Blood Pressure
Hypertension · Prehypertension
Primary: Resting Systolic Blood Pressure — 129.5; 127.9; 124.3; 123.6 mm Hg
N/A N=14 Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure
Diastolic Heart Failure · Hypertensive Heart Disease
Primary: Brachial Artery Flow-mediated Dilation (FMD) — 5; 8 % dilation — p=.17
N/A N=77 The Impact of a Resistance Training Intervention on Blood Pressure Control in Older Adults With Sarcopenia
Sarcopenia · High Blood Pressure · Hypertension
Primary: Change in Blood Pressure — 125.5; 131.4; 125.0; 127.5 mmHg
N/A N=337 SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
Hypertension · Vascular Diseases · Cardiovascular Diseases
Primary: Acute and Chronic Safety by Evaluating Incidence of Major Adverse Events — 204; 130; 2; 1 Participants
Phase 4 N=860 Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
Hypertension · Diabetes Mellitus
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -28.82; -26.22 mmHg
Phase 4 N=50 Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension
Pre-hypertension · Hypertension
Primary: Aortic Systolic Blood Pressure (SBP) — 112.7; 107.7; 106.2; 106.6 mm Hg